Economic evaluation of encorafenib with cetuximab in patients with BRAF V600E-mutant metastatic colorectal cancer in France: a cost-effectiveness analysis using data from the BEACON CRC randomised controlled trial.

Jean-Baptiste TrouillerBérengère MacabeoAndrew PollDan HowardAndy BucklandMarine SivignonEmilie ClayDavid MalkaEmmanuelle SamalinMondher ToumiPhilippe Laramée

Published in: BMJ open (2022)

This analysis showed encorafenib with cetuximab to be a cost-effective treatment in mCRC patients with a BRAF V600E mutation.

Keyphrases

metastatic colorectal cancer
study protocol
electronic health record
randomized controlled trial
big data
squamous cell carcinoma
radiation therapy
combination therapy
machine learning
artificial intelligence